Spectrophotometric Determination of Paracetamol and Orphenadrine Citrate in Tablet

LEON NEJEM, SAAD ANTAKLI* and HELEN BAGDASHE

Department of Chemistry, Faculty of Science, University of Aleppo, Aleppo, Syria

*Corresponding author: E-mail: antakli@scs-net.org

(Received: 20 January 2012;

Accepted: 30 August 2012)

AJC-12047

A simple and rapid spectrophotometric method has been developed to determine orphenadrine citrate and paracetamol in tablet formulations. The first step was based on the reaction of orphenadrine citrate with 1-amino naphthalene and sodium nitrite with heating for 6 min at 50 °C to give an orange colour having a maximum absorbance at 462 nm. The optimization of the reaction conditions is investigated. In the second step, paracetamol was analyzed after solving it in distilled water by taking the first order derivative spectroscopy and that to eliminate spectral interference with orphenadrine citrate. Beers law is obeyed in the concentration ranges 4.61-80.76 µg/mL and 0.75-30 µg/mL for orphenadrine citrate and paracetamol, respectively. The molar absorptivity, limit of detection, limit of quantification, Sandell sensitivity and linearity are also calculated. The average per cent recovery was found to be 99.90 ± 0.14 % for paracetamol and 99.80 ± 0.05 % for orphenadrine citrate.

Key Words: Paracetamol, Orphenadrine citrate, Spectrophotometric method.

INTRODUCTION

Orphenadrine citrate is chemically [(RS)-(dimethyl-2-(2-methyl-benzhydroxy)ethyl)amine citrate ($C_{18}H_{23}NO \cdot C_6H_8O_7$, m.w. 461.5 g/mol)] (Fig. 1-I), white or almost white, crystalline powder. Sparingly soluble in water, slightly soluble in alcohol. It contains not less than 98.5 % and not more than 101 % in its bulk powder¹. It is most widely employed as skeletal muscle relaxant. It acts centrally by depressing the appropriate neurons to prevent the generation of somatic molar nerve impulses.

Paracetamol is 4-hydroxyacetanilide; N-(4-hydroxyphenyl)-acetamide (Fig. 1-II), white odorless crystalline powder, sparingly soluble in water, freely soluble in alcohol, very slightly soluble in methylene chloride. It contains not less than 99 % and not more than 101 % in its bulk powder¹. It is a *p*-aminophenol derivative having analgesic and antipyretic properties and does not possess antiinflammatory activity. Combination of paracetamol and orphenadrine citrate shows an analgesic, antipyretic and skeletal muscle relaxing efficacy. Several methods have been applied in the literature for the determination of orphenadrine citrate and paracetamol in dosage forms and in biological fluids. Techniques such as spectrophotometry²⁻⁸, capillary electrophoresis⁹, high performance liquid chromatography (HPLC)¹⁰⁻¹³, FT-Raman spectroscopy¹⁴, flow-injection spectroscopic¹⁵ and fluorescence spectroscopy¹⁶ are reported in the literature for the estimation of paracetamol.

The concentration of orphenadrine citrate is almost 13 times lesser than paracetamol in its formulations and so simultaneous estimation would have much interference. To overcome this, we presented a new spectrophotometric method for determination of paracetamol and orphenadrine citrate. In order to determine paracetamol, the first order derivative was selected at 264.17 nm, while orphenadrine citrate was determined by forming an orange complex, resulting by the reaction of orphenadrine citrate with 1-amino naphthalene and sodium nitrite after heating for 6 min at 50 °C to give an orange colour having a maximum absorbance at 462 nm.

Fig. 1. I-Structure of Orphenadrine citrate II-Structure of paracetamol

EXPERIMENTAL

In this study, we used UV-visible double beam spectrophotometer T-80/T80+ (England), quartz cells 1 cm, analytical balance TE64 Sartorius sensitivity 0.01 mg. Digital water bath, pH meter (Inolap-Germany). Pipettes product of HGB (Germany). All chemicals were of analytical grade, sodium hydroxide, sodium acetate three hydrates, 1-amino naphthalene

and sodium nitrite (BDH Company), ethanol (Merck, Germany), bi-distilled water.

Drug products: We determined the quantity paracetamol and orphenadrine citrate 500 and 35 mg/tablet, respectively in some Syrian products, trade names: Tranpal (Amrit), Asiagesic (Asia) and Myoflex (syphco).

Reagents preparation

Paracetamol and orphenadrine citrate stock solutions:

The stock solutions of two drugs 1×10^{-3} mol/L were prepared separately by dissolving a suitable amount of drug powder in bi-distilled water at a boiling water bath for 5-10 min until complete dissolution of the analyte.

Reagent stock solution: 1-Amino naphthalene 2×10^{-3} mol/L was prepared by dissolving a suitable amount in 2 mL ethanol in 100 mL volumetric flask and then completing to volume with bi-distilled water.

Sodium nitrite 1×10^{-1} mol/L was also prepared by dissolving a suitable amount in bi-distilled water.

RESULTS AND DISCUSSION

Orphenadrine citrate analysis: Orphenadrine citrate reacts with 1-amino naphthalene and sodium nitrite solution with heating at 50 °C for 6 min to give an orange complex. The result solution was scanned in the range of wavelengths 300-600 nm against a blank of bi-distilled water and then measured the absorbance at maximum wavelength 462 nm. The linearity was in the concentration range 4.61-80.76 µg/mL. Molar absorptivity coefficient was $12161 \text{ L mol}^{-1} \text{ cm}^{-1}$. Limit of detection and limit of quantification were 0.89 and 2.7 µg/mL, respectively. Sandell sensitivity was 0.029 µg/cm^2 . We studied all the parameters of the coloured result solution to obtain the optimal conditions as the following:

Effect of temperature and time: We studied the effect of the temperature degree between 30-70 °C and heating time between 1 to 15 min. It is found that at 30, 35, 40 and 45 °C the absorbance continued in rising. Above of that, at 55 and 60 °C, the absorbance stayed constant, whereas at 65 and 70 °C a shifting peak has started and the absorbance decreased. So the optimum temperature was 50 °C for 6 min heating.

Sequence of addition and stability: The most favourable addition sequence was "1-amino naphthalene-sodium nitrite-drug" for obtaining the highest absorbance. The complex stability was at least 24 h.

Effect of reagent volume: To study the 1-amino naphthalene volume influence on the coloured solution, we made a series of 10 mL separation volumetric flask solution by adding 0.5 mL of orphenadrine citrate 1×10^{-3} mol/L, 1 mL of sodium nitrite 1×10^{-1} M and between (0.0-4.0 mL) of 1-amino naphthalene 1×10^{-3} M, then added 4 mL of ethanol and completed to 10 mL by bi-distilled water. The absorbance at 462 nm for every added of 1-amino naphthalene volume, against the blank of bi-distilled water was determined. It was found that the completed coloured complex formation was after 1 mL of 1-amino naphthalene solution as it is shown in Fig. 2. The same work was repeated for studying the effect of sodium nitrite volume 0.1 M in the volumes 0.1-1.2 mL and the best addition volume was 1 mL in this concentration (Fig. 3).

Fig. 2. Effect of volume 1-amino naphthalene

Fig. 3. Effect of volume sodium nitrite

Reaction ratios by molar ratio: To study the reaction ratios between orphenadrine citrate and 1-amino naphthalene, we made a series of 10 mL separation volumetric flask solutions by adding 0.5 mL of 1×10^{-3} M orphenadrine citrate and 1 mL of 1×10^{-1} M sodium nitrite, after we fixed a suitable volume and between 0.125-4.0 mL 1-amino naphthalene 1×10^{-3} M, followed by the addition of 4 mL of ethanol and make up the volume to 10 mL by bi-distilled water. The absorbance was measured at 462 nm for every added of 1-amino naphthalene volume, against the blank of bi-distilled water. It was found that the reaction ratio (orphenadrine citrate: 1-amino naphthalene) was (1:2) (Fig. 4).

Fig. 4. Orphenadrine citrate and 1-amino naphthalene reaction ratios by molar ratio

Reaction ratios by continuous variation: To study the reaction ratios by continuous variation between orphenadrine citrate and 1-amino naphthalene, we made a series of 10 mL separation volumetric-flask solutions. each one contains 1 mL

of sodium nitrite, X mL solution of orphenadrine citrate 1×10^{-3} M and Y mL 1-amino naphthalene 1×10^{-3} M (always $X+Y = \text{constant}$) respectively, we heated, added 5 mL ethanol and completed to 10 mL by bi-distilled water. We measured the absorbance at 462 nm for every added of orphenadrine citrate and 1-amino naphthalene volume, against the blank bi-distilled water. It was found that reaction ratio (orphenadrine citrate: 1-amino naphthalene) was (1:2) (Fig. 5).

Fig. 5. Orphenadrine citrate and 1-amino naphthalene reaction ratios by continuous variation

Complex formation constant ($\log K_c$): The complex formation constant was calculated after the molar ratio and the continuous variation as presented in Table-1.

Method	$\log K_c$	Average
Molar ratio	9.71	9.48
Continuous variation	9.24	

Paracetamol analysis: After preparation of the stock solution we made series of 10 mL separation volumetric-flask solutions and scanned the spectrum in the range 200-400 nm against the blank of bi-distilled water and then calculated the first order derivative from the software program. It is found that paracetamol had a good absorbance at 264.17 nm where the coloured complex and other components had zero absorbance at this wavelength. Molar absorptivity coefficient was $10104 \text{ L mol}^{-1} \text{ cm}^{-1}$, limit of detection and limit of quantification were: 0.22 and $0.66 \mu\text{g/mL}$ respectively. Sandell sensitivity was $0.075 \mu\text{g/cm}^2$.

Range and linearity of orphenadrine citrate: We studied the linearity orphenadrine citrate concentration at the optimal conditions where we made a series of 10 mL separated volumetric flasks each one contains 1 mL of 1-amino naphthalene 2×10^{-3} M, 1 mL of sodium nitrite 1×10^{-1} M and variable concentration of orphenadrine citrate stock solution 1×10^{-3} M, the constant concentration of paracetamol was added and heated, added 4 mL ethanol and then completed to 10 mL by bi-distilled water, finally measured the absorbance at 462 nm for each concentration against the blank bi-distilled water. Fig. 6 presents the orphenadrine citrate spectra. The range of linearity was obeyed to Beers law in concentration $4.61\text{--}80.76 \mu\text{g/mL}$ and the linearity is presented in Fig. 7.

Fig. 6. Spectra of orphenadrine citrate complex

Fig. 7. Linearity of orphenadrine citrate

Range and linearity of paracetamol: The same work for studying paracetamol linearity was done by adding a constant concentration of orphenadrine citrate and the same precedent volumes of 1-amino naphthalene, sodium nitrite and variable concentration of paracetamol stock solution, using the first order derivative at 264.17 nm (Fig. 8). It is found that linearity was obeyed Beers law in concentration $0.75\text{--}30 \mu\text{g/mL}$ and the linearity is presented in Fig. 9.

Fig. 8. First derivative spectra of paracetamol

Fig. 9. Linearity of paracetamol

TABLE-3
DETERMINATION OF PARACETAMOL AND ORPHENADRINE CITRATE IN
SOME SYRIAN TRADEMARKS TABLETS FORMULATIONS

Trade name	Company	Drug	Dose (mg)	X ₁	X ₂	X ₃	X ₄	X ₅	$\bar{X}$	Recovery (%)	RSD (%)	LC
Tranpal	Amrit	Paracetamol	450	449.7	449.70	449.7	448.2	449.7	449.40	99.86	0.14	0.83
		Orphenadrine citrate	35	34.9	34.90	35.4	35.4	34.0	34.92	99.77	1.63	0.70
Asiagesic	Asia	Paracetamol	450	451.1	445.00	449.8	449.8	449.8	449.10	99.80	0.52	0.92
		Orphenadrine citrate	35	34.5	35.30	35.6	34.0	35.3	34.94	99.82	1.90	0.82
Myoflex	Syphco	Paracetamol	450	449.7	450.59	449.7	449.7	451.1	450.14	100.03	0.14	0.78
		Orphenadrine citrate	35	34.5	34.90	34.5	35.0	35.8	34.94	99.82	1.52	0.65

LC = Limit of confidence.

Table-2 outlined the optimal parameters of the paracetamol and orphenadrine citrate.

TABLE-2
OPTIMAL SPECTROPHOTOMETRIC PARAMETERS OF
THE PARACETAMOL AND ORPHENADRINE CITRATE

Parameters	Paracetamol	Orphenadrine citrate
$\lambda_{\max}$ (nm)	264.17	462
Beer's law limit ($\mu\text{g/mL}$)	0.75-30	4.61-80.76
Molar absorptivity (L/mol cm)	12161	10104
Sandell's sensitivity ($\mu\text{g/cm}^2$)	0.075	0.029
Linear regression equation	$m = 0.003$ $b = 0.000$	$m = 0.024$ $b = 0.037$
Correlation coefficient	0.999	0.996
LOD ($\mu\text{g/mL}$)	0.22	0.89
LOQ ($\mu\text{g/mL}$)	0.66	2.7
Complex formation constant ($\log K_c$)	-	9.48

Analysis of commercial tablets: The proposed method has been applied for the analysis of paracetamol and orphenadrine citrate in their commercial tablet products. Twenty tablets were grounded and determined the tablet average weight. A quantity of powder equal to 500 mg paracetamol and 35 mg orphenadrine citrate was transferred to 500 mL volumetric-flask and completed to volume with bi-distilled water. The analyte was filtered and took a suitable volume to achieve the studied linearity. We added to it 1 mL 1-amino naphthalene and 1 mL sodium nitrite, then heated a mixture solution at 50 °C for 6 min, after that 4 mL of ethanol was added to make up the solution to 10 mL by bi-distilled water. Finally, the absorbance at 462 nm was measured and took the first order derivative from the application of the program at 264.17 nm. There were no interferences between drugs and tablet excipients. Table-3 presents the determination results of paracetamol and orphenadrine citrate in some Syrian commercial products.

Conclusion

We developed a new method which is suitable for the identification and quantification of the binary combination of

paracetamol and orphenadrine citrate in Syrian tablets formulation.

A good percentage of recovery shows that the method can be successfully used in a routine basis. The proposed method is simple, sensitive, rapid, specific, a little cost and could be applied for quality control of paracetamol and orphenadrine citrate.

ACKNOWLEDGEMENTS

This work was financially and technically supported by Ministry of High Education through University of Aleppo, Faculty of Science, Department of Analytical Chemistry in the University of Aleppo, Aleppo, Syria.

REFERENCES

1. The British Pharmacopoeia, British Pharmacopoeia Commission Office, Vol. I and II, p 4363, 3456 (2009).
2. L. Srathaphut and N. Ruangwises, *Yakugaku Zasshi, J. Pharm. Soc. (Japan)*, **120**, 1723 (2007).
3. N.W. Ali, M.R. Elghobashy, M. Gamal and M. Abdelkawy, J. First International Pharm. Sciences Conference (2009).
4. B.R. Shrestha and R.R. Pradhananga, *J. Nepal Chem. Soc.*, **24**, 39 (2009).
5. P. Ravikumar, M.M. Krishna, P.B. Prakash, B.A. Kumar and P. Madhusudhan, *E-J. Chem.*, **3**, 134 (2006).
6. H.M. Saleh, M.M. EL-Henawee, G.H. Ragab and S.S. Abd El-Hay, *J. Spectrochim. Acta A*, **67**, 1284 (2007).
7. S.A. Shama, *J. Pharm. Biomed. Anal.*, **30**, 1382 (2002).
8. S. Narayan, P. Kumar, R.K. Sindhu, A. Tiwari and M. Ghos, *Der. Pharma Chem.*, **1**, 72 (2009).
9. D.N. Haj-Ali and I.I. Hamdan, *Saudi Pharm. J.*, **18**, 233 (2010).
10. M.S. Arayne, N. Sultana and F.A. Siddiqui, *J. Chin. Chem. Soc.*, **56**, 169 (2009).
11. J.T. Franeta, D. Agbaba, S. Eric, S. Pavkov, M. Aleksic and S. Vladimirov, *IL Farmaco*, **57**, 709 (2002).
12. D.D. Borkar, V.P. Godse, Y.S. Bafana, A.V. Bhosale, *Int. J. Chem. Tech. Res.*, **1**, 667 (2009).
13. N.H. Krishnan, V. Gunasekaran, C. Roosewelt, K. Kalaivani, S. Chandrasekaran and V. Ravichandiran, *Asian J. Chem.*, **20**, 2557 (2008).
14. K. Kachrimanis, D.E. Braun and U.J. Griesser, *J. Pharm. Biom. Anal.*, **43**, 407 (2007).
15. M. Knochen, J. Giglio and B.F. Reis, *J. Pharm. Biomed. Anal.*, **33**, 191 (2003).
16. A.B. Moreira, H.P.M. Oliveira, T.D.Z. Atvars, I.L.T. Dias, G.O. Neto, E.A.G. Zagatto and L.T. Kubota, *J. Anal. Chim. Acta*, **539**, 257 (2005).